168 related articles for article (PubMed ID: 24598448)
1. A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma.
Monk P; Lam E; Mortazavi A; Kendra K; Lesinski GB; Mace TA; Geyer S; Carson WE; Tahiri S; Bhinder A; Clinton SK; Olencki T
J Immunother; 2014 Apr; 37(3):180-6. PubMed ID: 24598448
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
Escudier B; Lassau N; Angevin E; Soria JC; Chami L; Lamuraglia M; Zafarana E; Landreau V; Schwartz B; Brendel E; Armand JP; Robert C
Clin Cancer Res; 2007 Mar; 13(6):1801-9. PubMed ID: 17363536
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of sequential subcutaneous interleukin-2 plus interferon alpha followed by sorafenib in renal cell carcinoma (RCC).
Maroto JP; del Muro XG; Mellado B; Perez-Gracia JL; Andrés R; Cruz J; Gallardo E; Domenech M; Arranz JA; Meana JA
Clin Transl Oncol; 2013 Sep; 15(9):698-704. PubMed ID: 23359179
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.
Dasari A; Gore L; Messersmith WA; Diab S; Jimeno A; Weekes CD; Lewis KD; Drabkin HA; Flaig TW; Camidge DR
Invest New Drugs; 2013 Feb; 31(1):115-25. PubMed ID: 22415798
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
6. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma.
Cesana GC; DeRaffele G; Cohen S; Moroziewicz D; Mitcham J; Stoutenburg J; Cheung K; Hesdorffer C; Kim-Schulze S; Kaufman HL
J Clin Oncol; 2006 Mar; 24(7):1169-77. PubMed ID: 16505437
[TBL] [Abstract][Full Text] [Related]
7. Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma.
Bulgarelli J; Piccinini C; Petracci E; Pancisi E; Granato AM; de Rosa F; Guidoboni M; Petrini M; Ancarani V; Foschi G; Romeo A; Tontini L; De Giorgi U; Lolli C; Gentili G; Valmorri L; Rossi A; Ferroni F; Casadei C; Cortesi P; Crudi L; Ridolfi L
Front Immunol; 2021; 12():778459. PubMed ID: 34777395
[TBL] [Abstract][Full Text] [Related]
8. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients.
Desar IM; Jacobs JH; Hulsbergen-vandeKaa CA; Oyen WJ; Mulders PF; van der Graaf WT; Adema GJ; van Herpen CM; de Vries IJ
Int J Cancer; 2011 Jul; 129(2):507-12. PubMed ID: 20839259
[TBL] [Abstract][Full Text] [Related]
10. A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.
Larkin JM; Ferguson TR; Pickering LM; Edmonds K; James MG; Thomas K; Banerji U; Berns B; de Boer C; Gore ME
Br J Cancer; 2010 Oct; 103(8):1149-53. PubMed ID: 20842130
[TBL] [Abstract][Full Text] [Related]
11. The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2.
Yang JC; Topalian SL; Schwartzentruber DJ; Parkinson DR; Marincola FM; Weber JS; Seipp CA; White DE; Rosenberg SA
Cancer; 1995 Aug; 76(4):687-94. PubMed ID: 8625167
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer.
Ganesan P; Piha-Paul S; Naing A; Falchook G; Wheler J; Fu S; Hong DS; Kurzrock R; Janku F; Laday S; Bedikian AY; Kies M; Wolff RA; Tsimberidou AM
Invest New Drugs; 2014 Apr; 32(2):279-86. PubMed ID: 23756764
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.
Gollob JA; Sciambi CJ; Peterson BL; Richmond T; Thoreson M; Moran K; Dressman HK; Jelinek J; Issa JP
Clin Cancer Res; 2006 Aug; 12(15):4619-27. PubMed ID: 16899610
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib, but not sunitinib, induces regulatory T cells in the peripheral blood of patients with metastatic renal cell carcinoma.
Flörcken A; Takvorian A; Van Lessen A; Singh A; Hopfenmüller W; Dörken B; Pezzutto A; Westermann J
Anticancer Drugs; 2012 Mar; 23(3):298-302. PubMed ID: 22156795
[TBL] [Abstract][Full Text] [Related]
15. Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib.
Nakano K; Komatsu K; Kubo T; Natsui S; Nukui A; Kurokawa S; Kobayashi M; Morita T
Jpn J Clin Oncol; 2013 Oct; 43(10):1023-9. PubMed ID: 23956442
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response.
Ridolfi L; de Rosa F; Ridolfi R; Gentili G; Valmorri L; Scarpi E; Parisi E; Romeo A; Guidoboni M
J Transl Med; 2014 Sep; 12():262. PubMed ID: 25245327
[TBL] [Abstract][Full Text] [Related]
17. [Three Patients with Acute Myocardial Infarction Associated with Targeted Therapy of Sorafenib for Metastatic Renal Cell Carcinoma : Case Report].
Takagi K; Takai M; Kawata K; Horie K; Kikuchi M; Kato T; Mizutani K; Seike K; Tsuchiya T; Yasuda M; Yokoi S; Nakano M; Ushikoshi H; Miyazaki T; Deguchi T
Hinyokika Kiyo; 2015 Sep; 61(9):347-51. PubMed ID: 26497860
[TBL] [Abstract][Full Text] [Related]
18. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
19. [First-line therapy of advanced or metastasized renal cell carcinoma: phase III, open, randomized sequence study to examine efficacy and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of patients with advanced or metastasized renal cell carcinoma (SWITCH-2 - AN 33/11)].
Rexer H;
Urologe A; 2014 May; 53(5):735-8. PubMed ID: 24727992
[No Abstract] [Full Text] [Related]
20. A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor.
McDermott DF; Trehu EG; Mier JW; Sorce D; Rand W; Ronayne L; Kappler K; Clancy M; Klempner M; Atkins MB
Clin Cancer Res; 1998 May; 4(5):1203-13. PubMed ID: 9607578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]